Originally published In Press as doi:10.1074/jbc.M109386200 on February 21, 2002
J. Biol. Chem., Vol. 277, Issue 17, 14514-14520, April 26, 2002
Plasmodium falciparum Histidine-rich Protein-2
(PfHRP2) Modulates the Redox Activity of
Ferri-protoporphyrin IX (FePPIX)
PEROXIDASE-LIKE ACTIVITY OF THE PfHRP2-FePPIX
COMPLEX*
Ryuichi
Mashima
§,
Leann
Tilley¶,
Mary-Anne
Siomos¶,
Vicki
Papalexis¶,
Mark J.
Raftery
, and
Roland
Stocker
**
From the
Biochemistry Group, The Heart Research
Institute, 145 Missenden Road, Camperdown, New South Wales 2050, the
¶ Department of Biochemistry, La Trobe University, Bundoora,
Victoria 3086, and the
Cytokine Research Unit, School of
Pathology, University of New South Wales,
Kensington, New South Wales 2052, Australia
Received for publication, September 28, 2001, and in revised form, February 18, 2002
 |
ABSTRACT |
Histidine-rich protein-2 from Plasmodium
falciparum (PfHRP2) binds up to 50 molecules of
ferri-protoporphyrin IX (FePPIX) (Choi, C. Y., Cerda, J. F.,
Chu, H. A., Babcock, G. T., and Marletta, M. A. (1999)
Biochemistry 38, 16916-16924). We reasoned that the PfHRP2-FePPIX complex has antioxidant properties that could
be beneficial to the parasite. Therefore, we examined whether binding to PfHRP2 modulated the redox properties of FePPIX. We
observed that PfHRP2 completely inhibited the
auto-oxidation of ascorbate mediated by free FePPIX. We also
investigated the peroxidase activity of PfHRP2-FePPIX using
13-hydroperoxy-9,11-octadienoate (18:2-OOH) as substrate. Reaction of
PfHRP2-FePPIX with 18:2-OOH in the presence of added
reducing agents gave 13-hydroxy-9,11-octadienoate (18:2-OH) as a major
product and 13-keto-9,11-octadienoate (18:2=O) and 9,12,13-trihydroxy-10-octadecaenoate as minor products. Binding of
FePPIX to PfHRP2 lowered the rate of decomposition of
18:2-OOH and increased the 18:2-OH to 18:2=O ratio. Similar to other
authentic peroxidases, phenols, amines, and biological reductants like
ascorbate promoted 18:2-OH production, and NaCN inhibited 18:2-OH
production. Thioanisole also acted as a reductant and was converted to
thioanisole sulfoxide, suggesting formation of compound I during the
reaction. These data show that PfHRP2 modulates the redox
activity of FePPIX and that the PfHRP2-FePPIX
complex may have previously unrecognized antioxidant properties.
 |
INTRODUCTION |
During the blood stage of malaria infection, the parasite feeds on
red cell proteins, principally hemoglobin. Degradation of hemoglobin
takes place in the food vacuole, and this process is initiated by the
conversion of oxyhemoglobin to methemoglobin with the concomitant
production of superoxide anion that dismutates to
H2O2 (1). About 80% of the hemoglobin is
degraded during the intra-erythrocytic development of the parasite (2),
corresponding to ~15 mmol/liter H2O2 being
produced. H2O2 is a potentially harmful oxidant
that can cause damage to protein and lipid in the presence of
transition metals and reducing substances. Indeed, parasitized red
cells are exposed to oxidative stress (reviewed in Ref. 3).
A second toxic insult comes from ferri-protoporphyrin IX
(FePPIX)1 released as the
byproduct of methemoglobin degradation (1). Free FePPIX is toxic
because of its detergent-like (4) and redox properties (5). The
parasite detoxifies FePPIX via nonenzymatic processes, including
reaction with H2O2 and glutathione, that lead
to the accumulation of iron (6). In addition, FePPIX is crystallized to
a granular pigment, known as hemozoin (
-hematin) (7). This process
is initiated and accelerated by histidine-rich proteins, of
which Plasmodium falciparum histidine-rich protein-2 (PfHRP2) is characterized best. Histidine comprises 34% of
the amino acid residues of PfHRP2 (8, 9), and for effective conversion of FePPIX to
-hematin, the protein requires an acidic pH
that exists in the food vacuole (10, 11).
PfHRP2 is also present outside the food vacuole,
i.e. underneath the red cell membrane and in the erythrocyte
cytoplasm (12). This indicates a biological role for PfHRP2
at neutral pH where it acts as an efficient FePPIX-binding protein
rather than promoting
-hematin formation (11). Up to ~50 mol of
FePPIX binds tightly per mol of PfHRP2 through
hexa-coordination (13) to the repetitive amino acid sequence AHHAHHAAD
(14). Although the spectroscopic properties of the
PfHRP2-FePPIX complex are well characterized (13), its
biochemical properties are poorly understood. We reasoned that the
coordinated binding to PfHRP2 modulates the redox activity of FePPIX and that the PfHRP2-FePPIX complex may possess
peroxidase activity.
FePPIX-containing peroxidases reduce hydroperoxides (ROOH) via
heterolysis to the corresponding alcohol (ROH) and compound I (Reaction
1), an intermediate with an oxidation state two electrons higher than
that of the resting enzyme. In contrast, free FePPIX and the heme
proteins cytochrome P-450 and hemoglobin decompose ROOH through
homolysis to alkoxyl radical (RO·) and an oxo-ferryl species
(Reaction 2) (15). Catalytic reduction of ROOH requires consecutive
one-electron reduction of the FePPIX peroxidase intermediates compound
I (Reaction 3) and compound II (the one-electron oxidized form of the
enzyme) (Reaction 4), and this is achieved by hydrogen donors
(AH2) such as amines and phenols. Alternatively,
compound I can be reduced by sulfur- and nitrogen-containing compounds
such as thioanisole through oxygen transfer (Reaction 5) (16, 17).
In the present study, we investigated the redox properties of the
PfHRP2-FePPIX complex. We show that binding to
PfHRP2 decreases the pro-oxidant properties and increases
the peroxidase activity of FePPIX, raising the possibility that
PfHRP2 acts as a previously unrecognized antioxidant by
attenuating alkoxyl and hydroxyl radical formation.
 |
EXPERIMENTAL PROCEDURES |
Materials--
Linoleic acid, arachidonic acid,
o-phenylenediamine (OPD),
2,2'-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid), GSH,
N, N'-diphenyl-1,4-phenylenediamine, phenol, gallic acid,
salicylic acid, 1,2,4-aminotriazole, ferri-protoporphyrin IX (hematin,
FePPIX), and thioanisole were obtained from Sigma. NaCN and
NaN3 were from Merck, 1-palmitoyl-2-linoleoyl
phosphatidylcholine (PLPC) was from Avanti Polar-Lipids Inc.
(Alabaster, AL), and guaiacol was from Fluka (Buchs, Switzerland).
Bilirubin conjugate, protoporphyrin IX (PPIX), and tin protoporphyrin
IX (SnPPIX) were from Porphyrin Products (Logan, UT), and
Trolox® and zinc (II) protoporphyrin IX (ZnPPIX) from Aldrich.
[1-14C]Linoleic acid (55 mCi/mmol) and PD-10 columns were
from Amersham Biosciences. Unless specified otherwise, aqueous buffers
were stored over Chelex-100® (Bio-Rad) prior to use.
13-Hydroxy-9,11-octadienoate (18:2-OH) was prepared from 18:2-OOH as
described (18). 13-Keto-9,11-octadienoate (18:2=O) was prepared by
reduction of 18:2-OOH with acetylchloride in pyridine or purchased from
Cayman (Ann Arbor, MI).
Expression and Purification of Recombinant PfHRP2--
BL21/DE3
Escherichia coli (Stratagene, La Jolla, CA) transfected with
the pET-8c expression vector containing the recombinant PfHRP2 sequence (kindly donated by Drs. D. Sullivan and D. Goldberg, Howard Hughes Medical Institute) were grown overnight, and
protein expression was induced by
isopropyl-
-D-thiogalactopyranoside (0.84 mM). After incubation at 37 °C for 4 h, the
harvested cells were sonicated (XL2000, Daintree), and
PfHRP2 was purified from the supernatant using a
Ni2+-agarose column (Novagen) eluted with 20 mM
Tris-HCl (pH 7.9) containing 1 M imidazole. The recombinant
PfHRP2 used in this study contains 93 histidine residues and
binds 46 molecules of FePPIX/protein (13). Unless otherwise specified,
reconstitution was performed for 5 min at 37 °C in 50 mM
sodium phosphate buffer (pH 7.2) containing equimolar amounts of
PfHRP2 and FePPIX (13). For some experiments
PfHRP2 (1.1 µM) was reconstituted with
different metallo-porphyrins (100 µM) in 200 mM sodium phosphate buffer (pH 7.2) for 5 min at 37 °C.
Excess metallo-porphyrin was then removed by gel filtration (PD-10
column) using PBS as eluent.
Preparation of Lipid
Hydroperoxides--
15-Hydroperoxyeicosa-5,8,11,13-tetraenoic acid
(20:4-OOH), 18:2-OOH, and 1-palmitoyl-2-linoleoyl phosphatidylcholine
hydroperoxide (PLPC-OOH) were prepared by lipoxygenase-catalyzed
oxidation and purified by solid phase extraction (C18 cartridge,
Waters, Milford, MA) followed by preparative reversed-phase HPLC using
an LC-18 column (20 × 250 mm, 5 µm, Supelco, Bellofonte, PA)
(19). 18:2-OOH and 20:4-OOH were eluted with methanol/water/acetic acid
(950:50:1), whereas PLPC-OOH was eluted using 0.02% triethylamine in
methanol at 8.0 ml/min. [1-14C]18:2-OOH (55 mCi/mmol) was
prepared similarly, except that an analytical LC-18 column (4.6 × 250 mm, 5 µm, Supelco) was used, and the flow rate of the mobile
phase was 1.0 ml/min. The fractions containing the respective
hydroperoxide were collected, dried, and redissolved in methanol for
determination of the concentration at 234 nm using
M = 28,000 cm
1 (20).
Auto-oxidation and Co-oxidation Experiments--
The
time-dependent decay of ascorbate was used to examine the
ability of PfHRP2 to render catalytic metals inactive (21). Briefly, ascorbate (100 µM) was incubated at 37 °C in
nonchelexed PBS containing the additives specified, and the decay of
ascorbate followed at 265 nm. For co-oxidation experiments, PLPC (100 µM) was incubated in PBS containing 1 µM
PfHRP2, 5 µM FePPIX, 100 µM OPD
at 37 °C, and the time-dependent formation of PLPC-OOH was determined as described below.
Peroxidase Activity of PfHRP2--
The
time-dependent accumulation of 18:2-OH and 18:2=O from 5 µM 18:2-OOH was monitored at 37 °C in PBS containing 1 mM OPD and PfHRP2 reconstituted with FePPIX or
the metallo-porphyrin indicated. Control experiments contained either
FePPIX-free PfHRP2, FePPIX alone, or water as vehicle. At
the times indicated, the concentrations of 18:2-OH, 18:2-OOH, and
18:2=O were determined as described below. Where indicated, NaCN,
NaN3, or 1,2,4-aminotriazole (0-10 mM) was
added, in which case the peroxidase activity of 1 µM
PfHRP2 and 1 µM FePPIX was examined using 100 µM 18:2-OOH and 500 µM OPD in 50 mM sodium phosphate (pH 7.2) and an incubation period of 15 min.
Steady-state Kinetics--
The substrate specificity of
FePPIX-bound PfHRP2 was examined for 5 min at 37 °C in 50 mM phosphate buffer (pH 7.2) containing 1 µM
PfHRP2, 1 µM FePPIX, 100 µM
18:2-OOH, and 0-200 µM of the reducing substrate
indicated. Km and Vmax were
determined from the respective Michaelis-Menten plots obtained under
the same conditions using 100 µM OPD and 0-200
µM 18:2-OOH.
Involvement of Compound I in Peroxidase Activity of
PfHRP2--
The involvement of compound I in the peroxidase activity
of PfHRP2 was assessed by the conversion of thioanisole to
thioanisole sulfoxide (15). Briefly, FePPIX-containing
PfHRP2 (3 µM each) was incubated at 37 °C
in PBS containing 200 µM 18:2-OOH and 1.6 mM
thioanisole. The concentration of thioanisole sulfoxide was determined
by HPLC using an LC-18 column (4.6 × 150 mm, 3 µm, Supelco)
eluted with methanol/water (40:60) at 0.8 ml/min and monitored at 254 nm. Under these conditions, thioanisole sulfoxide (containing both
diasteromers) and thioanisole eluted at 4.3 and 44 min, respectively.
Quantification of thioanisole sulfoxide was by area comparison using an
authentic standard prepared from thioanisole by oxidation with
stoichiometric amounts of hydrogen peroxide.
Analyses of Oxidized Lipids--
The concentrations of 20:4-OOH,
18:2-OOH, 18:2-OH, and 18:2=O were determined by HPLC on an analytical
LC-18 column eluted with acetonitrile/water/acetic acid (60:40:0.1) at
1.0 ml/min. 20:4-OOH, 20:4-OH, 18:2-OOH, and 18:2-OH were detected at
234 nm, and 18:2=O was detected at 280 nm, and the compounds were quantified using
M = 28,000 and 22,000 cm
1
for the conjugated diene and oxodiene, respectively.
[1-14C]18:2-OOH and its decomposition products were
separated under the same chromatographic conditions, using a
radiometric detector A140 (Canberra Packard, Meriden, CT) and
Ultima-Gold (Canberra Packard) as scintillant. PLPC-OOH and its
corresponding hydroxide were quantified at 234 nm after separation on
an ODS column (4.6 × 250 mm, 5 µm; Phenomenex, Pennant
Hills, Australia) eluted with acetonitrile/methanol/water (50:49.5:0.5)
containing 10 mM choline chloride at 1.0 ml/min.
Mass Spectrometry--
The reaction products were analyzed by a
TSQ-7000 mass spectrometer (Finnigan MAT, San Jose, CA) operated in
negative electrospray ionization mode with the capillary voltage
set at
4.5 kV, capillary temperature at 180 °C, and scan time of
2 s. The samples (10 µl) were injected by direct flow injection.
The analytes were ionized using 0.005% ammonium acetate in
methanol/water (50:50) at 10 µl/min. The following values of
(deprotonated) masses were obtained: 18:2-OH, 295.0 (calculated,
295.5); 18:2=O, 293.0 (calculated, 293.4);
9,12,13-trihydroxyocta-10-decaenoic acid, 329.2 (calculated, 329.5).
For collision-induced dissociation experiments, the collision energy
was set at 56 eV, and 0.005% ammonium acetate was delivered at 5 µl/min.
 |
RESULTS |
Previous studies showed that FePPIX bound to PfHRP2 is
hexa-coordinated and bis-histidyl ligated (13). To test whether such binding modulates the redox properties of FePPIX, we first examined the
effect of FePPIX on the auto-oxidation of ascorbate in the absence
and presence of PfHRP2 in nonchelexed PBS. As expected, ascorbate auto-oxidized readily in the absence of PfHRP2
(Fig. 1). This auto-oxidation was
inhibited by chelex treatment of the buffer (not shown), as reported
previously (21), indicating that it was caused by catalytic metals
present in PBS. The addition of PfHRP2 did not significantly
alter the rate of ascorbate auto-oxidation (Fig. 1), indicating that
the protein was not able to prevent metal-catalyzed oxidation of
ascorbate. Inclusion of free FePPIX but not PfHRP2-ligated
FePPIX enhanced the rate of ascorbate oxidation (Fig. 1), indicating
that the protein can regulate the redox activity of FePPIX.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
Auto-oxidation of ascorbate. Ascorbate
(100 µM) was incubated at 37 °C in PBS containing 5 µM FePPIX ( ), 1 µM PfHRP2
( ), PfHRP2-FePPIX (1 µM PfHRP2
and 5 µM FePPIX, ), and PBS ( ). The data are
expressed as the means ± S.D. (n = 3).
|
|
FePPIX is the prosthetic group of several hydroperoxide-metabolizing
enzymes. To examine further the redox property of
PfHRP2-ligated FePPIX, we tested the peroxidase activity of
the complex using 18:2-OOH as substrate and OPD as reducing agent.
FePPIX rapidly decomposes 18:2-OOH to the corresponding hydroxy-,
keto-, and trihydroxy-fatty acids (22), a finding we confirmed (Fig.
2). Decomposition was almost
instantaneous (Fig. 2), with the hydroxy- and keto-fatty acids
accounting for 22 and 14%, respectively, of the starting material
(Table I). FePPIX and certain heme
proteins cause both hetero- and homolytic cleavage of 18:2-OOH to yield 18:2-OH and 18:2=O, respectively (22), whereas authentic peroxidases convert 18:2-OOH exclusively into 18:2-OH via heterolysis (Scheme 1). Thus, the ratio of 18:2-OH to 18:2=O
reflects the relative contribution of hetero- to homolytic degradation
of 18:2-OOH (22). Compared with FePPIX alone, the
PfHRP2-FePPIX complex significantly lowered the rate of
18:2-OOH decomposition (Fig. 2) and increased both the yield of 18:2-OH
and the ratio of 18:2-OH to 18:2=O (Table I). This product distribution
indicated an enhanced peroxidase-like activity of the
PfHRP2-FePPIX complex compared with FePPIX alone, although
it remained lower that that seen with GSH peroxidase (Table I).
Similarly, the presence of PfHRP2 doubled the turnover number for 18:2-OH compared with FePPIX alone, although again the value
for the PfHRP2-FePPIX complex remained lower than that of
GSH peroxidase (Table I). The metal chelators,
diethylenetriaminepentaacetic acid and EDTA, did not affect the
peroxidase-like activity of the PfHRP2-FePPIX complex (not
shown). A significant proportion of the 18:2-OOH degraded by the
PfHRP2-FePPIX complex was not recovered as 18:2-OH or
18:2=O. Separate experiments employing [1-14C]18:2-OOH as
substrate revealed 9,12,13-trihydroxyoctadecaenoic acid as a additional
product (Fig. 3).

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 2.
Degradation of 18:2-OOH by FePPIX and
PfHRP2-FePPIX. 18:2-OOH (5 µM) was
reacted at 37 °C with FePPIX alone ( ) or PfHRP2-FePPIX
(1 µM PfHRP2 and 1 µM FePPIX,
) in 50 mM sodium phosphate buffer (pH 7.2) in the
presence of 100 µM OPD. At the times indicated, the
18:2-OOH concentration was determined as described under
"Experimental Procedures." The data are expressed as the means ± S.D. (n = 3). Where error bars cannot be
seen, they are smaller than the size of the symbols.
|
|
View this table:
[in this window]
[in a new window]
|
Table I
Reaction of 18:2-OOH with PfHRP2-FePPIX
The peroxidase-like activities of PfHRP2-FePPIX (0.1 µM PfHRP2 and 5 µM FePPIX),
FePPIX (5 µM), or GSH peroxidase (0.16 µM
in selenium) was determined following incubation for 5 min at 37 °C
in 50 mM sodium phosphate buffer (pH 7.2) using 200 µM 18:2-OOH and 1 mM reducing substrate (OPD
for both PfHRP2-FePPIX and FePPIX and GSH for GSH
peroxidase). Concentrations of 18:2-OOH and its metabolites were
determined by HPLC on an LC18 column (4.6 × 150 mm, 3 µm) with
acetonitrile/water/acetic acid (60:40:0.1) at 1.0 ml/min. Quantitation
was performed by UV detection at 234 nm for 18:2-OH and 18:2-OOH and
280 nm for 18:2 O. The data are expressed as the means ± S.D.
of three experiments.
|
|

View larger version (30K):
[in this window]
[in a new window]
|
Fig. 3.
Reversed-phase HPLC chromatograms of 18:2-OOH
and its metabolites. A and B, 200 µM 18:2-OOH was added to 50 mM sodium
phosphate buffer (pH 7.2) containing PfHRP2-FePPIX (0.1 µM PfHRP2 and 5 µM FePPIX) at
37 °C for 5 min. Elution was performed isocratically with
acetonitrile/water/acetic acid (60:40:0.1) at a flow rate of 1.0 ml/min
on an LC-18 column (4.6 × 150 mm, 3 µm, Supelco). 18:2-OH and
18:2-OOH (A) and 18:2=O (B) were detected at 234 and 280 nm, respectively. C, 50 µM
[1-14C]18:2-OOH (55 mCi/mmol) was reacted in PBS
containing PfHRP2-FePPIX (1 µM
PfHRP2 and 1 µM FePPIX) at 37 °C for 15 min. Radioactivity was measured using a radiometric detector after
separation by reversed-phase HPLC as described above. The ratio of flow
rate of the mobile phase and scintillant was 3. Peaks 1-4
correspond to 18:2-OOH, 18:2-OH, 18:2=O, and
9,12,13-tirhydroxy-10-octadecaenoic acid, respectively (Scheme 1).
D, mass spectrum of 9,12,13-tirhydroxy-10-octadecaenoic acid
obtained by collision-induced dissociation experiment using negative
electrospray ionization. Mass spectrum was obtained by TSQ-7000 with
0.005% ammonium acetate in methanol/water (50:50) using
m/z = 329.2 as a precursor ion.
|
|
The above results further support the idea that PfHRP2 can
modulate the redox activity of FePPIX and that it decreases the proportion of homolytic degradation of 18:2-OOH. The latter pathway is
associated with the formation of alkoxyl radicals (Scheme 1) that can
co-oxidize suitable substrates (23, 24). We therefore incubated PLPC
with 18:2-OOH and FePPIX in the absence and presence of
PfHRP2. As expected, the presence of FePPIX caused the
time-dependent accumulation of PLPC-OOH (Fig.
4). PfHRP2 inhibited this
process by up to 50% (Fig. 4), demonstrating that the protein
inhibited the formation of potentially damaging alkoxyl radicals.

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 4.
Co-oxidation of PLPC. Co-oxidation of
132 µM PLPC was carried out at 37 °C in 50 mM sodium phosphate buffer (pH 7.2) containing 200 µM 18:2-OOH, 100 µM OPD, and either water
(control, ), PfHRP2 (1 µM, ), FePPIX (1 µM, ), or PfHRP2-FePPIX (1 µM
PfHRP2 and 1 µM FePPIX, ).
|
|
Increasing the FePPIX to PfHRP2 ratio resulted in an
increased extent of 18:2-OOH degradation (Fig.
5A) with unaltered product pattern (Fig. 5B). Also, pretreatment with NaCN, but not
azide or aminotriazole, inhibited the peroxidase activity of the
PfHRP2-FePPIX complex (Fig.
6), whereas the formation of 18:2=O was
unaffected (data not shown). This demonstrates that NaCN selectively
inhibited heterolytic cleavage of 18:2-OOH, and this rules out the
possibility that 18:2-OH is formed via alkoxyl radicals. Exposure to
NaCN caused a shift of the Soret band from 411 to 414 nm (Fig.
7) and a broadening of the
- and
-bands (Fig. 7, inset). The steady-state kinetics
of the reaction of PfHRP2-FePPIX with 18:2-OOH in the presence of OPD followed Michaelis-Menten kinetics (Fig.
8), consistent with peroxidase activity
of the complex. In general, amines and phenols acted as reducing agents
(Table II), suggesting that higher oxidation intermediates of PfHRP2-FePPIX participated in the
decomposition of 18:2-OOH (Reactions 3 and 4). Notably, ascorbate, a
potent reducing agent found in biological tissues including malaria
parasite-infected red cells (25), effectively promoted the reduction of
18:2-OOH. Tyrosine failed to act as a reducing agent, and its
incubation with PfHRP2-FePPIX in the presence of 18:2-OOH
failed to give rise to detectable amounts of di-tyrosine (not shown),
indicating that this physiologically readily available amino acid is
not likely to participate in redox reactions with
PfHRP2-FePPIX. PfHRP2-FePPIX also metabolized
20:4-OOH but not PLPC-OOH (Table III),
perhaps because of inaccessibility of the phospholipid hydroperoxide to the histidine residues of PfHRP2.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 5.
FePPIX-dependent formation of
18:2-OH and 18:2=O from 18:2-OOH. A, FePPIX (0-5
µM) was reconstituted with 0.1 µM
PfHRP2 and the formation of 18:2-OH ( ) and 18:2=O ( )
measured in 50 mM phosphate buffer (pH 7.2) containing 200 µM 18:2-OOH and 1 mM OPD at 37 °C for 5 min. B, ratio of 18:2-OH to 18:2=O produced under the
condition of varying FePPIX to PfHRP2 ratio used in
A. The concentrations of products were measured by HPLC as
described under "Experimental Procedures." The data are expressed
as the means ± S.D. (n = 3).
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 6.
Inhibition of the peroxidase activity of
PfHRP2-FePPIX. PfHRP2-FePPIX (1 µM PfHRP2 and 1 µM FePPIX) was
pretreated with increasing concentrations of NaCN ( ),
NaN3 ( ), or 1,2,4-aminotriazole ( ) in 50 mM sodium phosphate at pH 7.2 for 5 min at 37 °C. The
peroxidase activity was then assessed in PBS containing 100 µM 18:2-OOH and 500 µM OPD for 15 min at
37 °C by measuring the formation of 18:2-OH by HPLC as described
under "Experimental Procedures." The results are expressed as
percentages of activity observed in the absence of modulator,
i.e. 10 ± 1 µM 18:2-OH. The data are
expressed as the means ± S.D. (n = 3).
|
|

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 7.
Spectral changes of
PfHRP2-FePPIX induced by NaCN. PfHRP2
(0.56 µM) was reconstituted with FePPIX (5 µM) in 100 mM sodium phosphate at pH 7.2 for
5 min at 37 °C, and the PfHRP2-FePPIX complex then
reacted with 10 mM NaCN for 5 min at 37 °C. The spectra
were taken before ( ) and after (+) addition of NaCN. The
inset shows the spectra of PfHRP2 (0.56 µM) reconstituted with FePPIX (50 µM) in
the absence and presence of 10 mM NaCN. The results shown
are representative of three separate experiments.
|
|

View larger version (13K):
[in this window]
[in a new window]
|
Fig. 8.
Michaelis-Menten plots of peroxidase activity
of PfHRP2-FePPIX. Peroxidase activity of
PfHRP2-FePPIX (1 µM PfHRP2 and 1 µM FePPIX) was measured at 37 °C for 5 min in 50 mM sodium phosphate (pH 7.2) containing OPD (0-200
µM) and 100 µM 18:2-OOH (A) or
100 µM OPD and 18:2-OOH (0-200 µM)
(B). The production of 18:2-OH was measured by HPLC as
described under "Experimental Procedures." The data shown represent
the average values of an experiment performed in triplicate.
|
|
View this table:
[in this window]
[in a new window]
|
Table II
Steady-state kinetic parameters of PfHRP2-FePPIX
Km and Vmax values for different
reductants of PfHRP2-FePPIX were determined by incubating
PfHRP2-FePPIX (1 µM PfHRP2, 1 µM FePPIX), 18:2-OOH (100 µM), and the
reducing substance indicated (0-200 µM) for 5 min at
37 °C in 50 mM sodium phosphate buffer, pH 7.2. Accumulation of 18:2-OH was determined by HPLC as described under
"Experimental Procedures." The data were calculated from respective
Michaelis-Menten plots as shown in Fig. 8A and presented as
the mean values of an experiment carried out in triplicate.
|
|
View this table:
[in this window]
[in a new window]
|
Table III
Steady-state kinetic parameters of PfHRP2-FePPIX
Km and Vmax values for different
lipid hydroperoxides of PfHRP2-FePPIX were determined by
incubating PfHRP2-FePPIX (1 µM HRP2, 1 µM FePPIX), OPD (100 µM), and the lipid
hydroperoxide indicated (0-200 µM) for 5 min at 37 °C
in 50 mM sodium phosphate buffer, pH 7.2. Accumulation of
lipid hydroxide was determined by HPLC as described under
"Experimental Procedures." The data were obtained from
Michaelis-Menten plots as shown in Fig. 8B and presented as
the mean values of an experiment carried out in triplicate.
|
|
To test the involvement of compound I as a higher oxidation state
intermediate of PfHRP2-FePPIX, we examined whether
thioanisole could serve as a reducing agent (26). Consistent with
previous studies of peroxidases, the amount of thioanisole sulfoxide
formed during the reaction increased with increasing concentration of thioanisole and was comparable with the amount of accumulating 18:2-OH
(Fig. 9A). Also, the
accumulation of thioanisole sulfoxide increased with increasing
concentrations of 18:2-OOH (Fig. 9B) and FePPIX (Fig.
9C). Together, these results suggest that the reaction of
PfHRP2-FePPIX with 18:2-OOH gives rise to a compound I-like
intermediate.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 9.
Production of thioanisole sulfoxide by
PfHRP2-FePPIX. A, a mixture containing
3 µM PfHRP2, 3 µM FePPIX, and
200 µM 18:2-OOH was treated with thioanisole at 37 °C
for 15 min, and the production of thioanisole sulfoxide ( ) and
18:2-OH ( ) was determined by HPLC as described under "Experimental
Procedures." Similarly, the formation of thioanisole sulfoxide was
determined with 3 µM FePPIX, 3 µM
PfHRP2, 1.6 mM thioanisole, and various
concentrations of 18:2-OOH (B) and with 0-2
µM FePPIX, 3 µM PfHRP2, 1.6 mM thioanisole, 200 µM 18:2-OOH
(C), respectively. The data are expressed as the means ± S.D. (n = 3).
|
|
Finally, we examined whether complexes of PfHRP2
with other metallo-porphyrins exhibit peroxidase-like activity.
Consistent with a previous report (14), PfHRP2-bound
metallo-porphyrins gave rise to distinct Soret and
- and
-bands
(Fig. 10 and Table IV). In contrast to FePPIX, however,
complexes of PfHRP2 with SnPPIX or ZnPPIX, as well as PPIX
itself, essentially failed to reduce 18:2-OOH to 18:2-OH or 18:2=O
(Table V).

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 10.
UV-visible spectra of
PfHRP2 reconstituted with various
metallo-porphyrins. PfHRP2 was reconstituted with
metal-porphyrin in 200 mM sodium phosphate (pH 7.2)
containing 1.1 µM PfHRP2 and a suspension of
100 µM FePPIX, SnPPIX, ZnPPIX, or PPIX for 5 min at
37 °C. Unbound metallo-porphyrin was then removed by gel filtration
through a PD-10 column before the spectra of the reconstituted
PfHRP2 (0.56 µM) were recorded in PBS.
|
|
View this table:
[in this window]
[in a new window]
|
Table IV
Maximal wavelengths of absorption of PfHRP2 reconstituted with
different metallo-porphyrins
UV-visible spectra were recorded in PBS at room temperature.
|
|
View this table:
[in this window]
[in a new window]
|
Table V
Peroxidase activity of PfHRP2 reconstituted with different
metal-porphyrins
Peroxidase activity was determined by incubating the complex of
PfHRP2 and the (metal)-porphyrin indicated with 100 µM 18:2-OOH and 1 mM OPD in PBS for 15 min at
37 °C. 18:2-OH and 18:2 O were then quantified by HPLC as
described under "Experimental Procedures." The concentrations of
18:2-OH and 18:2 O accumulated were calculated after subtracting the
corresponding control value obtained in the absence of OPD. The data
are expressed as the means ± S.D. (n = 3).
|
|
 |
DISCUSSION |
The known function of PfHRP2 is to promote the
conversion of FePPIX to hemozoin, the malarial pigment (10). By doing
so, PfHRP2 converts the redox-active and toxic FePPIX into
insoluble hemozoin crystals that maintain pro-oxidant activity (27).
The enhancement of formation of hemozoin by PfHRP2 requires
acidic pH (11) and is generally considered to take place in the food vacuole of parasitized red cells where hemoglobin proteolysis occurs
(10). However, PfHRP2 is also detected in the cytoplasm and
plasma membrane of erythrocytes (12) as well as in the plasma of
infected hosts (28). The pH in these compartments is expected to be
neutral, i.e. a condition where PfHRP2 binds
FePPIX rather than initiates its conversion to hemozoin (11). Thus, the
experimental conditions employed here are relevant for sites where the
FePPIX crystallizing function of PfHRP2 is limited.
The present results suggest that at neutral pH, PfHRP2
modulates the redox activity of FePPIX. Thus, PfHRP2
protected ascorbate from degradation induced by FePPIX and transition
metals, it inhibited the release of radical intermediates during the
metabolism of lipid hydroperoxides mediated by FePPIX, and it increased
the peroxidase-like activity of FePPIX. Together, our results indicate a novel function for PfHRP2 as an antioxidant that could be
relevant to malaria-infected red cells that are under oxidative stress (3).
The binding of FePPIX to PfHRP2 at neutral pH has been
characterized previously in detail (13). Up to ~50 molecules of
FePPIX bind to each PfHRP2 protein and are tightly
coordinated to histidine residues. We reasoned that such binding may
modulate the redox activity of FePPIX, and our finding that the
PfHRP2-FePPIX complex has peroxidase activity supports this
view. True peroxidases catalyze the heterolytic reduction of
hydroperoxides to the corresponding alcohol (29). In contrast, free
FePPIX and FePPIX proteins such as hemoglobin and cytochrome P-450
metabolize hydroperoxides predominantly via homolytic reduction (15).
The two pathways can be distinguished by analyzing the stable products
formed during the reaction (22). The results of such analysis show that
the PfHRP2-FePPIX complex has higher peroxidase activity
than FePPIX alone, although the complex is not a true peroxidase in
that it also degrades ROOH through homolytic reactions.
The enhanced peroxidase activity of the PfHRP2-FePPIX
complex relative to free FePPIX is supported by several lines of
evidence, in addition to the higher ratio of hetero- to homolytic
products (Table I). Thus, the reaction catalyzed by the
PfHRP2-FePPIX complex followed Michaelis-Menten kinetics,
yielded higher turnover numbers for 18:2-OH than did FePPIX, and it was
inhibited by CN
that caused an irreversible change in the
spectral properties of the protein-bound FePPIX. Also, other
metallo-porphyrins were unable to replace FePPIX in the reaction. In
addition, the implied suppression of homolytic degradation pathways by
PfHRP2 is supported by the co-oxidation experiment; binding
of FePPIX to PfHRP2 attenuated the extent of alkoxyl radical
formation (Fig. 2). Together, these findings demonstrate the
peroxidase-like activity of the PfHRP2-FePPIX complex and
strongly suggest that FePPIX is the catalytic center for this activity.
Most heme-containing peroxidases contain a neutral amino acid residue
on the distal side of the heme that is believed to participate with the
distal histidine in the two-electron reduction of the hydroperoxide
substrate (30). This view is supported by the loss of peroxidase
activity of prostaglandin-endoperoxide synthase-2 in which the relevant
neutral amino acid residue glutamine is replaced by valine or arginine
(31). Interestingly, PfHRP2 lacks this distal neutral amino
acid (8), and this could explain the participation of
PfHRP2-FePPIX in homolytic reduction of the hydroperoxide
observed in the present study. In this context, it would be interesting
to examine the peroxidase activity of PfHRP3, a homologous
protein to PfHRP2 that contains asparagine instead of
aspartate distal to the heme and close to the distal histidine residue
(8).
Peroxidases reduce hydroperoxides to the corresponding alcohol with
concomitant formation of an intermediate called compound I that has
distinct spectral properties (29). Attempts to detect compound I during
PfHRP2-FePPIX-mediated reduction of 18:2-OOH failed, even
when using rapid scanning spectroscopy (dead time, 0.1 s) at
7 °C (data not shown), similar to the situation with methemoglobin
and metmyoglobin (32). However, the observed conversion of thioanisole
to thioanisole sulfoxide provides indirect evidence for the
intermediate formation of compound I (17). In particular, we observed
that the production of sulfoxide and 18:2-OH increases in parallel with
increasing thioanisole concentration (Fig. 3A), consistent
with the reduction of compound I by thioanisole. The putative
involvement of compound I implies that 18:2-OOH can displace a
coordinated histidine residue in PfHRP2-FePPIX. We consider the spectral changes observed upon the addition of CN
to
PfHRP2-FePPIX (Fig. 7, inset), indicative of a
change from hexa- to penta-coordinated heme (29), as precedence for the replacement of a coordinated histidine residue. Ligation of the other
histidine to FePPIX appeared to be maintained in the presence of
CN
, because the intensity of the Soret band did not
change (Fig. 7). That addition of CN
abolished the
formation of 18:2-OH but not that of 18:2=O suggests that
CN
prevents hydrogen donation from histidine, which is
required for peroxidase activity (29).
The physiological importance of the peroxidase-like activity of the
PfHRP2-FePPIX complex, if any, remains to be established. To
be physiologically relevant, PfHRP2-FePPIX and
hydroperoxide(s) must co-exist with a suitable reducing substrate, and
the peroxidase activity of the complex must effectively compete with
other existing peroxidases. The host cytosol of parasitized red cells
is a likely site where PfHRP2-FePPIX could act as a
peroxidase. Red cells contain ascorbate, a suitable reductant (Table
II), and the cellular concentration of the vitamin increases upon
malaria infection (33). Also, parasitized red cells contain increased
concentrations of polyunsaturated fatty acids and markers of lipid
oxidation (34), indicative of an increase in the formation of lipid
hydroperoxides. In addition, the activities of red cell glutathione
peroxidase and reductase decrease markedly during infection (2),
thereby increasing the likelihood of participation of other peroxidases or proteins with peroxidase-like activity. Furthermore, there is
evidence that both red cell PfHRP2 (35) and FePPIX co-exist outside the food vacuole.2
Although PfHRP2-FePPIX has only moderate peroxidase activity when compared with GSH peroxidase, PfHRP2 is concentrated at
sites such as underneath the red cell membrane where oxidative damage would be particularly harmful in the parasitized erythrocyte, i.e. if the host cell membrane lyses prematurely, the
parasite will not be able to complete the cycle. These considerations
together suggest that a role for PfHRP2-FePPIX in the
metabolism of lipid hydroperoxides in parasitized red cells is feasible
and that such a function of PfHRP2 provides a previously
unrecognized protection to the parasite against oxidative stress.
Additional studies are required to explore this possibility directly.
 |
ACKNOWLEDGEMENTS |
We thank Drs. Andrew Terentis, Stuart Linton
and Paul Witting (The Heart Research Institute) and Anthony Kettle
(Christchurch School of Medicine, Christchurch, New Zealand) for
helpful discussions. The excellent technical assistance of Dr. Aviva
Levina (School of Chemistry, University of Sydney) and access to mass
spectrometers at the Ray Williams Biomedical Mass Spectrometry Facility
(Faculty of Medicine, University of New South Wales) are also acknowledged.
 |
FOOTNOTES |
*
This work was supported by the Australian National Health
and Medical Research Council.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Present address: Centre for Thrombosis and Vascular Research,
School of Medical Sciences, University of New South Wales, UNSW Sydney,
New South Wales 2052, Australia.
**
To whom correspondence should be addressed: Centre for
Thrombosis and Vascular Research, School of Medical Sciences,
University of New South Wales, UNSW Sydney, New South Wales 2052, Australia. E-mail: r.stocker@unsw.edu.au.
Published, JBC Papers in Press, February 21, 2002, DOI 10.1074/jbc.M109386200
2
P. Loria, N. Campanale, M. Foley, and L. Tilley,
unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
FePPIX, ferri-protoporphyrin IX;
18:2=O, 13-ketooctadeca-9,11-dienoic acid;
18:2-OH, 13-hydroxyoctadeca-9,11-dienoic acid;
18:2-OOH, 13-hydroperoxyoctadeca-9,11-dienoic acid;
20:4-OOH, 15-hydroperoxyeicosa-5,8,11,13-tetraenoic acid;
HPLC, high-performance
liquid chromatography;
OPD, o-phenylenediamine;
PBS, phosphate-buffered saline;
PfHRP2, P. falciparum
histidine-rich protein-2;
PLPC, 1-palmitoyl-2-linoleoyl
phosphatidylcholine;
PLPC-OOH, 1-palmitoyl-2-linoleoyl
phosphatidylcholine hydroperoxide;
PPIX, protoporphyrin IX;
SnPPIX, tin
PPIX;
ZnPPIX, zinc (II) PPIX;
ROOH, hydroperoxide;
ROH, corresponding
alcohol;
RO·, alkoxyl radical;
AH2, hydrogen
donor.
 |
REFERENCES |
| 1.
|
Francis, S. E.,
Sullivan, D. J., Jr.,
and Goldberg, D. E.
(1997)
Annu. Rev. Microbiol.
51,
97-123[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Stocker, R.,
Hunt, N. H.,
Buffinton, G. D.,
Weidemann, M. J.,
Lewis-Hughes, P. H.,
and Clark, I. A.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
548-551[Abstract/Free Full Text]
|
| 3.
|
Hunt, N. H.,
and Stocker, R.
(1990)
Blood Cells
16,
499-526[Medline]
[Order article via Infotrieve]
|
| 4.
|
Chou, A. C.,
and Fitch, C. D.
(1981)
J. Clin. Invest.
68,
672-677[Medline]
[Order article via Infotrieve]
|
| 5.
|
Tappel, A. L.
(1953)
Arch. Biochem. Biophys.
44,
378-394
|
| 6.
|
Loria, P.,
Miller, S.,
Foley, M.,
and Tilley, L.
(1999)
Biochem. J.
339,
363-370
|
| 7.
|
Goldberg, D. E.,
Slater, A. F.,
Cerami, A.,
and Henderson, G. B.
(1990)
Proc. Natl. Acad. Sci. U. S. A.
87,
2931-2935[Abstract/Free Full Text]
|
| 8.
|
Wellems, T. E.,
and Howard, R. J.
(1986)
Proc. Natl. Acad. Sci. U. S. A.
83,
6065-6069[Abstract/Free Full Text]
|
| 9.
|
Panton, L. J.,
McPhie, P.,
Maloy, W. L.,
Wellems, T. E.,
Taylor, D. W.,
and Howard, R. J.
(1989)
Mol. Biochem. Parasitol.
35,
149-160[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Sullivan, D. J., Jr.,
Gluzman, I. Y.,
and Goldberg, D. E.
(1996)
Science
271,
219-222[Abstract]
|
| 11.
|
Lynn, A.,
Chandra, S.,
Malhotra, P.,
and Chauhan, V. S.
(1999)
FEBS Lett.
459,
267-271[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Howard, R. J.,
Uni, S.,
Aikawa, M.,
Aley, S. B.,
Leech, J. H.,
Lew, A. M.,
Wellems, T. E.,
Rener, J.,
and Taylor, D. W.
(1986)
J. Cell Biol.
103,
1269-1277[Abstract/Free Full Text]
|
| 13.
|
Choi, C. Y.,
Cerda, J. F.,
Chu, H. A.,
Babcock, G. T.,
and Marletta, M. A.
(1999)
Biochemistry
38,
16916-16924[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Ziegler, J.,
Chang, R. T.,
and Wright, D. W.
(1999)
J. Am. Chem. Soc.
121,
2395-2400[CrossRef]
|
| 15.
|
Marnett, L. J.,
and Kennedy, T. A.
(1995)
in
Cytochrome P450 Structure, Mechanism, and Biochemistry
(Ortiz de Montellano, P. R., ed)
, pp. 49-80, Plenum Publishing Corp., New York
|
| 16.
|
Ortiz de Montellano, P. R.,
and Catalano, C. E.
(1985)
J. Biol. Chem.
260,
9265-9271[Abstract/Free Full Text]
|
| 17.
|
Ple, P.,
and Marnett, L. J.
(1989)
J. Biol. Chem.
264,
13983-13993[Abstract/Free Full Text]
|
| 18.
|
Mashima, R.,
Onodera, K.,
and Yamamoto, Y.
(2000)
J. Lipid Res.
41,
109-115[Abstract/Free Full Text]
|
| 19.
|
Mashima, R.,
Yamamoto, Y.,
and Yoshimura, S.
(1998)
J. Lipid Res.
39,
1133-1140[Abstract/Free Full Text]
|
| 20.
|
Chan, H. W.,
and Levett, G.
(1977)
Lipids
12,
99-104[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Buettner, G. R.
(1988)
J. Biochem. Biophys. Methods
16,
27-40[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Dix, T. A.,
and Marnett, L. J.
(1985)
J. Biol. Chem.
260,
5351-5357[Abstract/Free Full Text]
|
| 23.
|
Samokyszyn, V. M.,
and Marnett, L. J.
(1987)
J. Biol. Chem.
262,
14119-14133[Abstract/Free Full Text]
|
| 24.
|
Ortiz de Montellano, P. R.,
and Grab, L. A.
(1987)
Biochemistry
26,
5310-5314[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Stocker, R.,
Hunt, N. H.,
Weidemann, M. J.,
and Clark, I. A.
(1986)
Biochim. Biophys. Acta
876,
294-299[Medline]
[Order article via Infotrieve]
|
| 26.
|
Harris, R. Z.,
Newmyer, S. L.,
and Ortiz de Montellano, P. R.
(1993)
J. Biol. Chem.
268,
1637-1645[Abstract/Free Full Text]
|
| 27.
|
Green, M. D.,
Xiao, L.,
and Lal, A. A.
(1996)
Mol. Biochem. Parasitol.
83,
183-188[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Parra, M. E.,
Evans, C. B.,
and Taylor, D. W.
(1991)
J. Clin. Microbiol.
29,
1629-1634[Abstract/Free Full Text]
|
| 29.
|
Dunford, H. B.
(1999)
Heme Peroxidases
, pp. 1-507, John Wiley & Sons, Inc., New York
|
| 30.
|
Poulos, T. L.,
and Kraut, J.
(1980)
J. Biol. Chem.
255,
8199-8205[Free Full Text]
|
| 31.
|
Landino, L. M.,
Crews, B. C.,
Gierse, J. K.,
Hauser, S. D.,
and Marnett, L. J.
(1997)
J. Biol. Chem.
272,
21565-21574[Abstract/Free Full Text]
|
| 32.
|
Egawa, T.,
Shimada, H.,
and Ishimura, Y.
(2000)
J. Biol. Chem.
275,
34858-34866[Abstract/Free Full Text]
|
| 33.
|
Stocker, R.,
Weidemann, M. J.,
and Hunt, N. H.
(1986)
Biochim. Biophys. Acta
881,
391-397[Medline]
[Order article via Infotrieve]
|
| 34.
|
Stocker, R.,
Cowden, W. B.,
Tellam, R. L.,
Weidemann, M. J.,
and Hunt, N. H.
(1987)
Lipids
22,
51-57[CrossRef][Medline]
[Order article via Infotrieve]
|
| 35.
|
Papalexis, V.,
Siomos, M.-A.,
Campanale, N.,
Guo, X.-G.,
Kocak, G.,
Foley, M.,
and Tilley, L.
(2001)
Mol. Biochem. Pharmacol.
115,
77-86
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
C. Spycher, N. Klonis, T. Spielmann, E. Kump, S. Steiger, L. Tilley, and H.-P. Beck
MAHRP-1, a Novel Plasmodium falciparum Histidine-rich Protein, Binds Ferriprotoporphyrin IX and Localizes to the Maurer's Clefts
J. Biol. Chem.,
September 12, 2003;
278(37):
35373 - 35383.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Campanale, C. Nickel, C. A. Daubenberger, D. A. Wehlan, J. J. Gorman, N. Klonis, K. Becker, and L. Tilley
Identification and Characterization of Heme-interacting Proteins in the Malaria Parasite, Plasmodium falciparum
|